ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Exagen Inc

Exagen Inc (XGN)

3.17
-0.12
(-3.65%)
Closed 12 January 8:00AM
3.16
-0.01
(-0.32%)
After Hours: 11:59AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
3.17
Bid
2.97
Offer
4.50
Volume
51,598
3.05 Day's Range 3.31
1.3003 52 Week Range 6.21
Market Cap
Previous Close
3.29
Open
3.27
Last Trade
1
@
3.32
Last Trade Time
Financial Volume
US$ 163,152
VWAP
3.162
Average Volume (3m)
119,573
Shares Outstanding
17,637,278
Dividend Yield
-
PE Ratio
-2.35
Earnings Per Share (EPS)
-1.34
Revenue
52.55M
Net Profit
-23.69M

About Exagen Inc

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differentia... Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Exagen Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker XGN. The last closing price for Exagen was US$3.29. Over the last year, Exagen shares have traded in a share price range of US$ 1.3003 to US$ 6.21.

Exagen currently has 17,637,278 shares in issue. The market capitalisation of Exagen is US$58.03 million. Exagen has a price to earnings ratio (PE ratio) of -2.35.

XGN Latest News

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic...

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the...

Exagen Inc. Reports Third Quarter 2024 Results

Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments...

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024...

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0642.06052801033.1063.9832008893.46974133CS
4-2.8065-46.95892244625.97656.1931939824.34835724CS
120.3914.02877697842.786.212.381195734.37702043CS
261.2867.72486772491.896.211.78816833.82672768CS
521.0851.67464114832.096.211.3003605703.1930574CS
156-7.82-71.155595996410.9910.991.3003470323.69830765CS
260-21.05-86.9116432724.22271.3003471448.36659285CS

XGN - Frequently Asked Questions (FAQ)

What is the current Exagen share price?
The current share price of Exagen is US$ 3.17
How many Exagen shares are in issue?
Exagen has 17,637,278 shares in issue
What is the market cap of Exagen?
The market capitalisation of Exagen is USD 58.03M
What is the 1 year trading range for Exagen share price?
Exagen has traded in the range of US$ 1.3003 to US$ 6.21 during the past year
What is the PE ratio of Exagen?
The price to earnings ratio of Exagen is -2.35
What is the cash to sales ratio of Exagen?
The cash to sales ratio of Exagen is 1.06
What is the reporting currency for Exagen?
Exagen reports financial results in USD
What is the latest annual turnover for Exagen?
The latest annual turnover of Exagen is USD 52.55M
What is the latest annual profit for Exagen?
The latest annual profit of Exagen is USD -23.69M
What is the registered address of Exagen?
The registered address for Exagen is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Exagen website address?
The website address for Exagen is www.exagen.com
Which industry sector does Exagen operate in?
Exagen operates in the MEDICAL LABORATORIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

Discussion

View Full Feed
ORCA ORCA 4 minutes ago
BRO 1 MILLION SHARES DID DAMAGE??LMAO.IS THE CD THAT HATES TO SEE ANY SELLER.
AXXA
Don Faton Don Faton 4 minutes ago
Email got hacked unfortunately my twitter page has the new one.   Thanks PB 
SRNW
Don Faton Don Faton 6 minutes ago
Can we be all friends.  

I would like to know when sharp will tweet again and pull his head out of his ass. 

When we getting the supposed name and ticker change.  Nothing like the stock price bleeding down. As usual.  So frustrating 
WNFT
EmpressMonk25 EmpressMonk25 9 minutes ago
If you did your homework, it was clear the company had impressive products; the fault in progress was with Gensler, and the price was actually rock bottom. If you didn’t this, then maybe you weren't watching?
HMBL
jimr1717 jimr1717 10 minutes ago
🏆️ Filed a Form S-1 Registration Statement,
are offering shares of the Company's common stock to the public.
As soon as practicable after the effective date of this Registration Statement.

PROSPECTUS
All Things Mobile Analytic, Inc.
30,000,000 Share
ATMH
jondoeuk jondoeuk 10 minutes ago
KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.
NVCR
Golden Cross Golden Cross 10 minutes ago
$ILLR Triller is the Majority owner of Bare Knuckle Fighting Championship (#BKFC).
This is just one major part of Triller!

1. Triller is Majority Owner of BKFC.
2. World Famous Conor McGregor is Part-Owner
3. $25 Million Tournament Coming up!
4. BKFC is the
ILLR
Golden Cross Golden Cross 12 minutes ago
$ILLR Triller is the Majority owner of Bare Knuckle Fighting Championship (#BKFC).
This is just one major part of Triller!

1. Triller is Majority Owner of BKFC.
2. World Famous Conor McGregor is Part-Owner
3. $25 Million Tournament Coming up!
4. BKFC is the
ILLR
Kool Aid Man Kool Aid Man 12 minutes ago
I can't wait for the PR explaining the need for 700 million more shares. Never ending source of entertainment
SPZI
dstock07734 dstock07734 13 minutes ago
Gary,

I strongly suggest you go through the details of all the outcome measures adopted in the combo trial. They are so disruptive. I also think we should abandon the old concept about the definition of phase on clinical trials. The phase definition for DCVax-L doesn't matter. What it
NWBO
manibiotech manibiotech 13 minutes ago
Yep you did get it straight .
There is a reason companies apply to FDA and EMA . And there is reason for current SP.
But problem is that when given  straight to you , you can't comprehend straightforward reasons 
NWBO
Lime Time Lime Time 14 minutes ago
Very good opportunity
GVSI
gshores gshores 18 minutes ago
Nothing personal, but you reek of desperation for some reason. Longs will do great here.
SPZI
jondoeuk jondoeuk 19 minutes ago
Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma
NVCR
kBletsgo30 kBletsgo30 20 minutes ago
Yeah right 
RSPI
ddls ddls 21 minutes ago
Maybe you should double down, buy 10M shares...😎

Just watch out for these types of days..."1/3/25, Buy: 1,300,000, Neutral: 366,005, Sell: 66,963,117.😎

You'll be seeing more of them.
BIEL
XMaster2023 XMaster2023 25 minutes ago
I would take your bet but you have the ethics of someone who would work for an idiot who would try to kill a cure for cancer. Thus, I would never trust you!
NWBO
manibiotech manibiotech 27 minutes ago
And someone to pay NWBO ( not advent ) for those treatments 
NWBO
StockItOut StockItOut 29 minutes ago
Are they really? That's evidence of a scam.
XERI
skitahoe skitahoe 30 minutes ago
Dstocks, it's clear that many are interested in the kind of work we're doing. My question is, are any beyond the Phase 1/2 trials.

I believe we're clearly the leaders here and with approvals while it may make it easier for others, they'll still be many years before the can possibly g
NWBO
vinmantoo vinmantoo 31 minutes ago
Have you seen the stock price?

Enough said.

The stock price alone certainly isn't enough said.
Eagle1 Eagle1 34 minutes ago
SDCRBS, Please let me know if I can help you in any way. Just DM me. I'm sorry and sad to see all this CA and LA destruction.

I'm in the Houston area and couldn't imagine this type of destruction.

So Sorry.
GDVM
Plasmode Plasmode 39 minutes ago
I’ve learned so much from valuable contributors like Mr C and Dino and great respects for your researches and insights, then this kind of bickering just knock you off the pedestal into muck. Just respond with ‘next’ if you refuse to lower yourself into the mud. I have more respect for people like
TGLO
elks elks 39 minutes ago
Tic toc
GVSI
jondoeuk jondoeuk 41 minutes ago
Translational data from the PhI B-cell lymphomas trial demonstrated primary, secondary and tertiary tissue trafficking and clearance of CD19+ cells. That should help enable an immune reset in autoimmune diseases.

The next-gen CAR-T's will incorporate a suite of novel synthetic edits t
FATE

Your Recent History

Delayed Upgrade Clock